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Abstract
Neuroblastoma is a malignant neoplasm of the developing sympathetic nervous system that is notable for its phenotypic
diversity. High-risk patients typically have widely disseminated disease at diagnosis and a poor survival probability, but low-
risk patients frequently have localized tumors that are almost always cured with little or no chemotherapy. Our genome-
wide association study (GWAS) has identified common variants within FLJ22536, BARD1, and LMO1 as significantly
associated with neuroblastoma and more robustly associated with high-risk disease. Here we show that a GWAS focused on
low-risk cases identified SNPs within DUSP12 at 1q23.3 (P=2.07610
26), DDX4 and IL31RA both at 5q11.2 (P=2.94610
26 and
6.54610
27 respectively), and HSD17B12 at 11p11.2 (P=4.20610
27) as being associated with the less aggressive form of the
disease. These data demonstrate the importance of robust phenotypic data in GWAS analyses and identify additional
susceptibility variants for neuroblastoma.
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Introduction
Neuroblastoma is a pediatric cancer of the developing
sympathetic nervous system and is the most common childhood
solid tumor outside the central nervous system [1,2]. Its broad
spectrum of clinical behaviors is the basis for ways to categorize
neuroblastoma into three risk groups: high-risk, intermediate-risk
and low-risk. The approximately 50% of cases classified as high-
risk show an aggressive clinical course with widespread metastases
to bone and bone marrow present at diagnosis [3]. Despite
intensive multimodal therapy, the long-term survival rate is less
than 50% for children with high-risk neuroblastoma [1]. On the
other hand, substantial portions of neuroblastoma patients show
favorable clinical features including spontaneous regression of
disease, and are classified as low-risk. Low-risk neuroblastoma
patients have a greater than 95% survival probability with
minimal, if any, chemotherapy [1]. Intermediate-risk cases are
the most heterogeneous, and also the smallest subset using current
definitions, comprising about 15% of all neuroblastoma patients.
We have recently performed a neuroblastoma GWAS by
applying single marker analyses and identified three distinct loci
significantly associated with neuroblastoma. Each of these SNP
associations was within genes and particularly enriched in the
high-risk group of patients: FLJ22536 at chromosome 6p22 [4],
BRCA1 associated RING domain 1 (BARD1) at 2q35 [5], and LIM
domain only 1 (LMO1) at 11p15 [6]. A similar approach was
utilized to identify a common copy number variation (CNV) at
chromosome 1q21 within the NBPF23 gene that is also robustly
associated with neuroblastoma [7].
In this study, we report that by adapting statistical methods to
analyze genotype data, we discovered, and successfully replicated,
three distinct loci as associated with the low-risk group of
neuroblastoma. Furthermore, we report several gene sets as
enriched in all risk groups of neuroblastoma.
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Gene-centric method identifies three low-risk
neuroblastoma susceptibility loci
As we are interested in studying disease causal variants that have
a high likelihood of impacting protein-encoding genes, we
developed a gene-centric computational method to test for
association signals at the gene level. This method adapted the
global test [8], developed to test association of genes groups using
microarray expression data, to analyze our genotype data. Our
method computes an aggregated test score based on genotype data
of all SNPs on a region extending 10 kilo-bases upstream and
downstream of a gene. We applied this method using a discovery
set containing 1627 cases and 2575 control subjects, aimed at
analyzing association to 15,885 genes annotated in the UCSC
Genome Browser [9] (Materials and Methods). The replication
dataset contained 398 cases and 1507 control subjects. Our
methodology correctly identified the three significant genes
already reported (FLJ22536, BARD1 and LMO1). In addition,
our method also identified the dual-specificity phosphatase 12
gene (DUSP12) at chromosome band 1q23.3 (Table 1) as
significantly associated with neuroblastoma.
We next sought to determine if association signals discovered in
our unbiased scan would be further enriched, or diminished, when
we restricted our analyses to the divergent phenotypes of low-risk
or high-risk neuroblastoma. We first analyzed a subset of 678 high-
risk neuroblastoma cases from the original discovery case series,
again matched to 2575 control subjects. This analysis reconfirmed
that all three previously reported signals were truly associated with
high-risk neuroblastoma (Table 1), but DUSP12 did not show a
strong association signal in the high-risk disease case series
(P=4.56610
204). In parallel, we analyzed a subset of 574 low-
risk cases and 1722 matched control subjects and a replication set
of 124 cases and 496 matched control subjects (Materials and
Methods). This analysis confirmed DUSP12 and three novel genes
as associated with low-risk neuroblastoma: DEAD (Asp-Glu-Ala-
Asp) box polypeptide 4 isoform (DDX4) and interleukin-31
receptor A precursor (IL31RA) both at the same locus within
chromosome band 5q11.2, and hydroxysteroid (17-beta) dehydro-
genase 12 (HSD17B12) at chromosome band 11p11.2 (Table 1).
All signals had significant discovery p-values using Bonferroni
correction over 15,885 genes (P,3.15610
26), and replication p-
values less than 0.05.
Our gene-centric method was able to detect DUSP12 and
HSD17B12, the only two genes containing at least one SNP that
passed the Bonferroni correction in single marker (SNP) analysis of
the low-risk neuroblastoma (Figure 1 and Figure 2) using
association testing as implemented in PLINK [10]. The fact that
our gene-centric results were compatible with the single marker
results supported the effectiveness of our method. In addition, we
were able to detect two gene-level association signals located at a
single locus for DDX4 and IL31RA even though these genes did not
contain any significant SNPs in the single marker analysis (Figure 1
and Table 2). These genes, however, contained several SNPs with
moderate signals (Figure 2), and our gene-centric method was able
to combine these effects and detected the overall significance of
these two gene’s signals. Being independently replicated in our
study (P=7.20610
23 and 1.48610
22 respectively), these two
signals offered indications that our gene-centric method was more
Table 1. Summary of gene-centric analysis results for different phenotypic neuroblastomas.
Gene
Symbols Chromosome Start- Stop
N6 of
SNP
Overall
Discovery
P-values
Overall
Replication
P-values
High-risk
Discovery
P-values
High-risk
Replication
P-values
Low-risk
Discovery
P-values
Low-risk
Replication
P-values
BARD1 2q35 215301519-
215382673
28 9.92610
211 2.19610
203 ,1.00610
230 3.00610
203 1.62610
201 6.49610
201
FLJ44180 6p22.3 22243164-
22255401
8 ,1.00610
230 1.94610
204 ,1.00610
230 5.45610
203 1.40610
203 3.66610
202
LMO1 11p15.4 8202432-8246758 29 1.80610
207 1.59610
203 2.51610
208 2.82610
202 1.40610
202 5.46610
202
DUSP12 1q23.3 159986204-
159993576
4 1.16610
207 3.30610
202 4.56610
204 1.97610
201 2.07610
206 2.92610
202
DDX4 5q11.2 55070534-
55148362
11 2.81610
205 3.11610
203 2.95610
202 2.67610
201 2.94610
206 7.20610
203
IL31RA 5q11.2 55183090-
55254434
18 2.75610
204 5.74610
202 2.88610
201 7.28610
201 6.54610
207 1.48610
202
HSD17B12 11p11.2 43658718-
43834745
22 1.29610
204 3.05610
202 6.82610
202 3.82610
201 4.20610
207 5.37610
202
Bold-faced p-values indicate significant association signals with Bonferroni correction over 15,885 genes.
doi:10.1371/journal.pgen.1002026.t001
Author Summary
Neuroblastoma is the most common solid tumor outside
the central nervous system and is accountable for 10% of
the mortality rate of all children’s cancers. It has distinctive
clinical behaviors and is categorized into different risk
groups: high-risk, intermediate-risk, and low-risk. Genome-
wide associationstudieshavereported anumberof genetic
variations predisposing to high-risk neuroblastoma. This
study focuses on the low-risk neuroblastoma group and
identifies four novel genes (DUSP12, DDX4, IL31RA, and
HSD17B12) at three distinct genomic positions that harbor
disease-causing variants. This study also reports several
gene setsthatareenrichedinoverallneuroblastoma as well
as in both high-risk and low-risk groups. Also of importance
is that this study adopts a new computational method that
identifies genes, instead of only one single nucleotide
polymorphism, as disease-causing variants. Shown to have
superior power of detection genome-wide association
signals for neuroblastoma, the methodology presented in
this study has great potential applications in case-control
association studies in other diseases.
Low-Risk Neuroblastoma Susceptibility Loci
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association signals. Indeed, our power computation, adjusting for
15,885 tests, indicated that our method performed far better than
the single SNP method in both our discovery and replication case
series (Figures S1, S2, S3, S4).
To further confirm the validity of our discovery, we computed a
randomization p-value for each of the four newly discovered
genes. For each of these genes, we computed a separate null test
statistic distribution by calculating the gene-centric test statistics of
one million randomly selected pseudo-genes. These pseudo-genes
were selected to contain the same number of SNPs as were
contained in the referenced gene. This method of selecting
pseudo-genes was based on our observation that the average gene-
based test statistic was strongly correlated with the number of
SNPs in these genes (Figure S5), Using these null distributions to
compare against the observed test statistics of the four newly
discovered genes, we arrived at the randomization p-values
(Table 2). These p-values (range 2.0610
25–1.0610
26) were
compatible with the p-values asymptotically computed by our
gene-centric method, and notably strengthened the credibility of
the discovery of four novel disease causal genes associated with
low-risk neuroblastoma.
To assess the joint impact on disease risk of these genes, we
estimated the two-locus genotype odd ratios for all pairs amongst
the four most significant SNPs within these four genes (Table 3).
For each SNP pair tested, the independently contributed disease
risks for carriers of risk alleles at only one locus were overall
slightly stronger than the disease risks of each SNP when
analyzed separately. In all but one case, the odd ratios of disease
risks for carriers of both risk alleles increased markedly (odd
ratios range from 2.505 to 3.435). However, no significant
interaction between these SNP pairs was detected (P ranges from
0.459 to 0.909). Further, we computed all SNP pair interactions
amongst all four genes and again noticed no significant SNP-
Figure 1. Manhattan plot of single marker analysis of the low-risk neuroblastoma data set. Even though the genes DDX4 and IL31RA do
not contain significantly associated SNPs (P=1.0610
207), the combined effect of moderately associated SNPs drives these two genes to be significant
in our gene-centric analysis (genome-wide gene centric threshold p-values for significance is P,3.15610
26).
doi:10.1371/journal.pgen.1002026.g001
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from 0.108 to 0.523, Table S1). In the special case of DDX4
and IL31RA, the modest disease risk for carriers of both risk
alleles implicated the true association signal encompassed both
genes though they are 38 kilo-bases apart from each other
(Figure S6).
Figure 2. Haplotype view of the 4 genes significantly associated with low-risk neuroblastoma. Red line indicates P,1.0610
27. Only
DUSP12 and HSD17B12 contain SNPs with significant single-marker p-values in neuroblastoma low-risk subset. While DDX4 and IL31RA do not contain
significant SNPs, our gene-centric method was able to detect these genes as associated with low-risk neuroblastoma.
doi:10.1371/journal.pgen.1002026.g002
Low-Risk Neuroblastoma Susceptibility Loci
PLoS Genetics | www.plosgenetics.org 4 March 2011 | Volume 7 | Issue 3 | e1002026Lastly, we sought to further replicate our results in an
independent cohort in Italy of 115 low-risk cases and 680 controls.
We selected to genotype the three most significant SNPs
(rs1027702, rs2619046, rs11037575) in the three loci that contain
DUSP12, DDX4/IL31RA, and HSD17B12 respectively. We
analyzed these SNPs data sing various statistical tests listed in
Table 4. Interestingly, rs1027702 showed strong replication signals
for allele frequency association test as well as dominant model
association test (P=0.031 and 0.008 respectively). On the other
hand, both rs2619046, rs11037575 showed strong significant
signals for homozygous association test (P=0.042 and 0.028
respectively) as well as recessive model association test (P=0.047
and 0.037 respectively). Overall, these replication results provide
unambiguous evidence to confirm these three loci as significantly
associated with low-risk neuroblastoma.
Gene-set analyses identify enriched gene sets in all
phenotypes
We are also interested in gene set analyses to identify specific
pathways and gene sets that are enriched in neuroblastoma. To
perform this analysis, we adapted the random-set approach,
which was developed to analyze gene set analysis using gene
expression data. This method [11] was suitable for our purpose
since it required gene-level scores, which were conveniently
obtained by taking the logarithm transformation of our gene-
centric p-values.
We appliedthis random-set procedure using the overall, high-risk
and low-risk data sets described earlier over 4734 gene sets obtained
from the Gene Set Enrichment Analysis site [12], and selected
enriched gene sets based on Bonferroni correction criterion
(P,1.05610
25). Additionally selected based on replication p-value
threshold of 0.05, three Gene Ontology [13] sets were associated
with all cases of neuroblastoma: Nuclear Ubiquitin Ligase Complex,
Negative Regulation of Intracellular Transport, and Regulation of Phosphor-
ylation (Table 5). The first two gene sets were also significantly
enriched in high-risk neuroblastoma (P=1.275610
209 and
6.332610
207 respectively) with significant replication p-values
(0.030 and 0.036 respectively). The third gene set appeared to be
enriched in low-risk neuroblastoma (P=1.678610
206); however,
we were unable to replicate this result (P=0.96). Furthermore, we
identified and successfully replicated an additional gene set that was
exclusively enriched in low-risk neuroblastoma: Cytokine and
Chemokine Mediate Signaling Pathway (discovery P=8.175610
206 and
replication P=0.040). The identification of these gene sets may
elucidate biological pathways that are important in the biology of
neuroblastoma.
Discussion
Taken together, this study implicates DUSP12, DDX4, IL31RA,
and HSD17B12 as neuroblastoma susceptibility genes, with
particular relevance for those at low-risk for malignant progression
and death from disease. Methodologically, we suggest that the
Table 2. Additional summaries of gene-centric analysis results for low-risk neuroblastoma.
Gene
Symbols Chromosome Start- Stop
N6 of
SNP
Gene Randomi-
zation P-values
Most
significant SNP
Most significant
SNP P-values
Single SNP
Replication P range
DUSP12 1q23.3 159986204-159993576 4 2.00610
205 rs1027702 5.74610
28 2.32610
24–8.32610
22
DDX4 5q11.2 55070534-55148362 11 1.00610
206 rs2619046 6.41610
27 1.15610
23–9.50610
21
IL31RA 5q11.2 55183090-55254434 18 1.00610
206 rs10055201 4.80610
26 7.09610
24–9.28610
21
HSD17B12 11p11.2 43658718-43834745 22 1.00610
206 rs11037575 2.77610
29 1.49610
26–8.28610
21
Bold-faced p-values indicate significant signal in single marker analysis using Bonferroni correction over 479,811 SNPs.
doi:10.1371/journal.pgen.1002026.t002
Table 3. Estimates of low-risk neuroblastoma odd ratios by genotype between the most significant SNPs.
Gene 1
Most
significant
SNP 1
Single marker
SNP1 OR
(95% CI) P
SNP1 carrier
& SNP2 non-
carrier OR
(95% CI) P Gene 2
Most
significant
SNP 2
Single marker
SNP2 OR
(95% CI) P
SNP2 carrier
& SNP1 non-carrier
OR
(95% CI) P
SNP1 & SNP2
carrier OR
(95% CI) P
Inter-
action P
DUSP12 rs1027702 2.012 (1.47–2.79)
3.381610
206
2.373 (1.48–3.98)
1.217610
204
DDX1 rs2619046 1.477 (1.21–1.79)
5.702610
205
1.826 (0.97–3.49)
5.018610
202
3.435 (2.13–5.76)
1.123610
208
0.904
DUSP12 rs1027702 2.012 (1.47–2.79)
3.381610
206
2.108 (1.35–1.39)
4.308610
204
IL31RA rs10055201 1.494 (1.23–1.81)
3.848610
205
1.622 (0.87–3.04)
0.132
3.140 (2.00–5.07)
2.276610
208
0.627
DUSP12 rs1027702 2.012 (1.47–2.79)
3.381610
206
2.018 (1.11–3.93)
1.753610
202
HSD17B12 rs11037575 1.674 (1.35–2.08)
1.075610
206
1.715 (0.87–3.57)
0.122
3.379 (1.90–6.47)
3.148610
206
0.778
DDX1 rs2619046 1.477 (1.21–1.79)
5.702610
205
1.346 (0.85–2.08)
0.170
IL31RA rs10055201 1.494 (1.23–1.81)
3.848610
205
1.288 (0.58–2.68)
0.451
1.561 (1.27–1.91)
1.193610
205
0.459
DDX1 rs2619046 1.477 (1.21–1.79)
5.702610
205
1.546 (1.07–2.24)
1.828610
202
HSD17B12 rs11037575 1.674 (1.35–2.08)
1.075610
206
1.732 (1.27–2.39)
3.645610
204
2.534 (1.85–3.49)
6.632610
210
0.728
IL31RA rs10055201 1.494 (1.23–1.81)
3.848610
205
1.485 (1.02–2.15)
3.453610
202
HSD17B12 rs11037575 1.674 (1.35–2.08)
1.075610
206
1.665 (1.24–2.26)
4.805610
204
2.505 (1.84–3.42)
5.091610
210
0.909
Odd Ratios (OR), Confident Intervals (CI) and P-values (P) were computed from Fisher’s exact test. No significant interaction was detected between any pairs of most
significant SNPs.
doi:10.1371/journal.pgen.1002026.t003
Low-Risk Neuroblastoma Susceptibility Loci
PLoS Genetics | www.plosgenetics.org 5 March 2011 | Volume 7 | Issue 3 | e1002026gene-centric method has stronger power of detection of association
signals compared to the single marker method (Figures S1, S2, S3,
S4). Not only was the gene-centric method able to detect the two
genes harboring genome-wide significant SNPs (DUSP12 and
HSD17B12), but also it was able to detect 2 genes that would have
been missed by the single marker analysis (DDX4 and IL31RA).
Since this method was originally developed to analyze gene
expression data, its limitation is the lack of ability to take into
account the haplotype effect in computing gene level test statistics.
However, our efforts to replicate the discovery with two
independent cohorts unequivocally verify association signals at
these loci. Further studies will be required to determine if these
common variations tag cis- or trans-acting disease causal
variations. Interestingly, the segregation of gene-level association
signals and gene set enrichment scores between high-risk and low-
risk neuroblastoma (Table 1 and Table 5) supports the view that
common variation in the human genome can predisposed not only
to a particular disease, but also to a clinically relevant disease
subsets, thus demonstrating the power of robust phenotypic data in
GWAS efforts.
Materials and Methods
Subjects and quality control
Study subjects. The neuroblastoma patients in this study
were children registered through the North American-based
Children’s Oncology Group (COG) and were diagnosed with
neuroblastoma or ganglioneuroblastoma. Blood samples from the
neuroblastoma cases were identified through the COG
neuroblastoma repository for specimen collection at time of
diagnosis. All specimens were annotated with clinical and genomic
information (Table S2). Samples were assigned into three risk
groups (low-risk, intermediate-risk and high-risk) based on the
COG risk assignment algorithm [1], that includes patient age at
diagnosis [14], International Neuroblastoma Staging System
(INSS) stage [2], tumor histopathology [15], DNA index [16],
and MYCN amplification status [17]. The only eligibility criterion
for genotyping was availability of 1.5 mg of high quality DNA from
a tumor-free source such as peripheral blood or bone marrow cells
uninvolved with tumor. Since neuroblastoma in the United States
is demographically a disease of Caucasian of European
descendent, we limited our analyses to this ethnic group to
minimize genetic heterogeneity. Summaries of clinical and
genomic information of our discovery and replication cohorts
are provided in Table S2.
The control group in this study included 2575 children of self-
reported Caucasian ancestry who were recruited and genotyped
by the Center for Applied Genomics at the Children’s Hospital of
Philadelphia (CHOP). Eligibility criteria for control subjects
were: 1) self-reported Caucasian; 2) availability of 1.5 mgo fh i g h
quality DNA from peripheral blood or mononuclear bone
marrow cells; and 3) no known medical disorder, including
cancer, based on self-reported intake questionnaire and/or
clinician-based assessments.
The CHOP Institutional Review Board approved this study.
Genotyping and quality control for discovery cohort. SNP
genotyping was performed using the Illumina Infinium II
BeadChip (Illumina, San Diego, CA, USA) according to
methods detailed elsewhere [4], [5]. Since a portion of the
individuals in the discovery cohort was genotyped by the
HumanHap550 v1 array (n=859) while others were genotyped
by the v3 array (n=768), our analysis only concerned the markers
shared by the v1 and v3 array. The HumanHap550 v1 array
contains 555,175 markers, while the v3 array contains 561,288
markers, including 544,902 markers that are shared by the two
arrays. We filtered out 8,749 SNP markers with call rate less than
95%. We also excluded 5,415 SNP markers whose Hardy-
Weinberg Equilibrium p-values were less than 0.001. Finally, we
excluded additional 50,869 SNP markers whose minor allele
frequency is less than 5%.
Table 4. Single SNP replication results in Italian cohort (n=115 low-risk neuroblastoma and 680 controls).
Genes SNP
Discovery
Single Marker
TREND Test
Replication
Allele
Frequency Test
Replication
Homozygous
Model Test
Replication
Dominant
Model Test
Replication
Recessive
Model Test
DUSP12 rs1027702 5.74610
208 0.031 0.102 0.008 0.490
DD64/IL31RA rs2619046 6.41610
207 0.129 0.042 0.343 0.047
HSD17B12 rs11037575 2.77610
209 0.053 0.028 0.194 0.037
Bold-faced p-values indicate significant replication P-values,0.05.
doi:10.1371/journal.pgen.1002026.t004
Table 5. Summary of gene set analysis results for all, high-risk, and low-risk neuroblastoma.
Gene Set Names
N6 of
genes
Overall
Discovery
p-values
Overall
Replication
p-values
High-risk
Discovery
p-values
High-risk
Replication
p-values
Low-risk
Discovery
p-values
Low-risk
Replication
p-values
Nuclear Ubiquitin Ligase Complex 10 1.084610
209 6.620610
203 1.275610
209 3.024610
202 0.469 0.753
Negative Regulation of Intracellular Transport 10 5.692610
207 1.160610
202 6.332610
207 3.610610
202 0.361 0.184
Regulation of Phosphorylation 42 6.020610
207 4.142610
202 2.940610
202 0.925 1.678610
206 0.960
Cytokine and Chemokine Mediate Signaling
Pathway
18 0.109 0.756 0.813 0.928 8.175610
206 4.027610
202
Bold face p-values of different gene sets at different risk groups (overall, high-risk, low-risk) indicate significant enrichment of that gene set in that risk group.
doi:10.1371/journal.pgen.1002026.t005
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PLoS Genetics | www.plosgenetics.org 6 March 2011 | Volume 7 | Issue 3 | e1002026A total of 96 cases were removed from our data set due to their
low genotype call rate (,95%). Furthermore, we used Multi-
Dimensional Scaling (MDS) as implemented in the PLINK [10],
for inferring population structure (Figure S7). Comparing self-
identified ancestry with MDS-inferred ancestry confirmed 1642
neuroblastoma patients of European ancestry. Finally, we
calculated genome-wide identity-by-state (IBS) estimates for all
pair-wise comparisons among all case subjects and control subjects
to detect cryptic relatedness and potential duplicated genotype
within our data set. This step further excluded 15 neuroblastoma
patients from our analyses.
After all quality control steps, our discovery data set contained
1627 neuroblastoma case subjects of European ancestry, each of
which contained 479,811 SNP markers. To correct the potential
effects of population structure, 2575 matching control subjects of
European ancestry were selected based on their low IBS estimates
with case subjects. The genomic control inflation factor for this
data set was 1.08.
Five hundred and seventy four (574) low-risk cases, selected
from the above 1627 cases, were included for all low-risk
neuroblastoma analyses. To keep the genomic inflation factor
low, three best matching control subjects were selected for each
case, based on IBS estimates, making a total of 1722 control
subjects included for analyses. The genomic control inflation
factor for this data set was 1.07.
Genotyping and quality control for initial replication
cohort. SNP genotyping was performed using the Illumina
Human610-Quad array that includes both SNP and CNV
markers. The Human610-Quad array contains 620,901 SNPs.
We filtered out 48,831 SNP markers with call rate less than 95%.
We also excluded 13,305 SNP markers whose Hardy-Weinberg
Equilibrium p-values were less than 0.001. Finally, we excluded
additional 49,057 SNP markers whose minor allele frequency was
less than 5%. A total of 15 cases were removed from our data set
due to their low genotype call rate (,95%). After all quality
control steps, our replication data set contained 398 neuro-
blastoma case subjects of European ancestry, each of which
contained 509,708 SNP markers. To correct the potential effects
of population structure, 1507 matching control subjects of
European ancestry were selected based on their low IBS esti-
mates with case subjects.
One hundred and twenty four (124) low-risk cases, selected from
the above 398 cases, were included for all low-risk neuroblastoma
replication analyses. For each case, four best matching control
subjects were selected based on IBS estimates, making a total of
496 control subjects included for analyses.
Genotyping of second replication cohort. One hundred
and fifteen (115) low-risk neuroblastoma subjects for Italy and six
hundred and eighty (680) control Italian subjects were selected to
be genotyped at three SNPs: rs1027702, rs2619046, and
rs11037575. All samples were genotyped by Taqman SNP
Genotyping Assay by Applied Biosystems.
Statistical analyses
Gene-centric analysis. Our gene-centric analysis adopted
theglobaltestmethod [8],developed totestassociationofagroup of
genes using microarray data. First, to mirror gene expression data,
we quantified our SNP genotype data by counting the number of
minor alleles for each sample at each SNP. Second, due to the
analogy inrelative relationship of thetwo conceptsin global test and
in our study, we substituted the concepts of ‘‘genes’’ and ‘‘group of
genes’’ from global test with ‘‘SNPs’’ and ‘‘genes’’ respectively.
This method adopted the generalized linear model framework
to model the relationship between Y, a vector of clinical outcomes,
and X, the n6m matrix of genotypic data of n subjects and m SNPs.
In this model, a is the intercept, b is a length m vector of regression
coefficients, and h is a general link function such as the logit
function
EY ijb ðÞ ~h{1 az
X m
j~1
xijbj
 !
Testing association between genotypic data and clinical
outcomes is equivalent to testing the null hypothesis H0:
b1=b2=…=bm=0. Since the number of SNP is much larger
than the number of subjects, it is not possible to test this hypothesis
in a classical way. Instead, we could test H0 if we assume b1,…,bm
to be samples from a common distribution with expectation zero
and variance t
2. The null hypothesis becomes simply H0: t
2=0.I f
we rewrite the model in terms ri =gjxijbj, with i=1,…,n, then ri is
the linear predictor, the total effect of all covariates for subject i.
Let r=(r1,…,rn), then r is a random vector with expectation zero
and Cov(r)=t
2XX. The original model simplifies to
EY ijri ðÞ ~h{1 azri ðÞ
This is a simple random effect model. Under the null
hypothesis, the test statistic
Q~
Y{m ðÞ
0RY {m ðÞ
m2
has expectation E(Q) =trace(R) and variance:
Var Q ðÞ ~2trace R2   
z
m4
m2
2
{3
   X
i R2
i
where R=(1/m)XX’i sa nn6n matrix proportional to the
covariance matrix of the random effects r, m=h
21(a) is the
expectation of Y under H0, and m2 and m4 are the second and
fourth central moments of Y under H0.
The test statistic Q could be rewritten as
Q~
1
m
X m
i~1
1
m2
X0
i Y{m ðÞ
   2
where Xi is the length n vector of genotype of SNP i. The
expression Qi=(1/m2)[Xi’ (Y-m)]
2 would be exactly the test
statistic of SNP i if it were the only SNP on the gene of
interested; or we could interpret that Qi is the ‘‘contribution’’ of
SNP i to the overall test statistic. This means that the overall test
statistic is simply the average of the statistics Q1,…, Qm of m
individual SNPs. Notably, the averaging is over a squared
covariance between genotype and clinical outcomes, SNPs with
large variance (i.e. strong association signals) have stronger
influences on the outcome of the test statistic Q than those with
weaker association signals.
Using this method, we computed an aggregated effect of all
SNPs that are located from 10-kilo bases upstream to 10-kilo bases
downstream for the gene being tested, and computed asymptotic
p-value for each gene. We performed the global test on 15,885
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UCSC Genome Browser [9], and used strict Bonferroni correction
criterion (P,3.15610
26) to determine whether a gene was
associated with neuroblastoma. True association signals were
further selected based on replication p-value less than 0.05.
Randomization p-value computation. For each significant
gene, we computed randomization p-values by comparing its test
statistic and its respective null distributions. A null distribution of a
gene was composed of test statistics of one million pseudo-genes
having the samenumber of SNPs as the referenced genes. The SNPs
of these pseudo-genes were randomly selected across the genome.
Odd ratios estimation. We used the Fisher’s exact test to
estimate the odd ratios using genotype data as well as the 95%
confident interval and p-values.
SNP-SNP interaction estimation. Single marker interac-
tion scores were computed using the general linear model to
compute interaction effect between two SNPs.
Gene set analysis. To analyze the significance of gene sets,
we adopted the random-set method [11] since it allows us to utilize
the gene-centric results to compute enrichment score for each gene
set. In this analysis, we used the logarithm transformation of our
gene-centric method as gene-level scores to detect gene sets
enriched in neuroblastoma.
We performed three separate gene set analyses for overall, high-
risk and low-risk data sets over 4734 gene sets downloaded from
the Broad Institute MsigDb [12]. These gene sets include five
categories: positional gene sets, curated gene sets (chemical and genetic
perturbations, and canonical pathways), motif gene sets (microRNA
targets, and transcription factor targets), computational gene sets
(cancer modules, and cancer gene neighborhoods), and GO gene sets
(GO cellular components, GO biological process, and GO
molecular function). Strict Bonferroni correction criterion was
used to select gene sets that are enriched in neuroblastoma.
Data deposition
The genotypic and phenotypic information from this study is
deposited in dbGAP (www.ncbi.nlm.gov/gap) under accession
number phs000124.v2.p1.
Ethics statement
The Children’s Hospital of Philadelphia Institutional Review
Board approved this study.
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Figure S5 The correlation between average test statistic of genes
and the number of SNPs on those genes.
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Figure S6 Single SNP association signals of 610 kilo-base region
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mapped to these two genes respectively.
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Figure S7 Multi-dimensional scaling plot. Circled area denotes
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